



فقيه.

مجموعة فقيه للرعاية الصحية  
Fakeeh Care Group

فقيه.

# INVESTORS PRESENTATION


## 1Q-2026



# AGENDA

1. Strategic Updates
2. Financial Performance Overview
3. Expansion Program Updates
4. Q&A

# Fakeeh Care Group's integrated ecosystem is purpose-built to deliver market leading patient outcomes at scale



<sup>1</sup>Rolling 12 months basis covering 1Q26, 4Q25, 3Q25, and 2Q25 against the same periods of the previous year. <sup>2</sup>Refers to the average number of active students during the 12 months leading to March 2026. <sup>3</sup>Hospital and bed count includes: DSFH Jeddah (400 beds), DSFH Riyadh (185 beds), Neom (50 beds) and DSFH Madinah (200 beds, commenced operations in April 2025); <sup>4</sup>As of 31<sup>st</sup> of March 2026

# Fakeeh Care Group expands its footprint in Riyadh

## Dr. Mohammed Al-Fagih Hospital

Riyadh, Kingdom of Saudi Arabia  
Multi-specialty general hospital • CBAHI top-tier accreditation



STAKE  
**100%**

Expected closing in June 2026

CONSIDERATION  
**SAR 1.6bn**

Cash deal

Hospital Inaugurated  
**October 2022**

Completing 3 years of ramp-up

Total Built Up Area  
**93k sqm**

Comprising main & adjacent building

Bed Capacity  
**350**

Operational beds are 238 as of 4Q25

Clinics Capacity  
**192**

Current active clinics are 109 clinics

FY25 Patients Served  
**535,000+**

Growing by over 16% YoY

FY25 REVENUE  
**SAR 465mn+**

Growing at a CAGR of 38%+

## STRATEGIC RATIONALE

**SAR 112mn+**

FY25 EBITDA

**Sizeable, profitable asset**

350-bed multi-specialty hospital, operationally profitable since FY24. The hospital is expected to maintain its ramp up trajectory and continue its profitable growth.

**+47%**

Capacity headroom

**Latent capacity in existing building**

Operating at 68% beds utilized out of maximum capacity. 175 incremental beds and 83 additional clinics commissionable with no additional CAPEX.

**Time to market**

Opportunity leverage

**Premium catchment, top-tier asset**

A greenfield would require a c.4 years development timeline with significant execution risks; this acquisition offers an immediate market entry & positions us ahead of the new supply expected in Riyadh market

**535 Beds**

Combined Riyadh beds

**Triples our Riyadh presence instantly**

It's located in Central-East Riyadh high-density, fastest-growing market. Combines with DSFH Riyadh (185 beds) to create a 535-bed two-site cluster with shared strategic resources and potential synergy creation.

**3 segments**

Cash + MoH + Insurance

**Diversifies payer and patient mix**

Complements our VIP class offering in Riyadh by adding Cash, Network 6 / Class B insurance exposure as well as MOH. Reduces concentration risk in Riyadh and across the Kingdom.

## POTENTIAL IMPACT ON FAKEEH CARE GROUP'S CONSOLIDATION

**EPS accretive**

Immediate uplift to the Group's Net Profit & Attributable Net Profit

**Increased free cash flows**

No CAPEX in the medium term; generates strong free cash flows exceeding its loan repayments

**Synergy potential**

Combination will lead to operational efficiencies, cost savings & enhanced revenue opportunities; greater combined value

**Margin uplift**

Generates positive free cashflow & profitable since 2024; the hospital has an EBITDA margin of 24% as of FY25

**Revenue Diversification**

Diversify the Group's Jeddah patient base by adding footprint in a high-density & underserved catchment area

✓ Due Diligence & Negotiations → ✓ SPA Executed → Regulatory approvals → Closing (Expected June 2026)

# DSFH Jeddah reaffirms its commitment to quality care, earning recognition among the world's leading hospitals

World's Best Hospitals 2026 – Top 250 Q Saudi Arabia

Rank	Hospital Name	Country	City	State (US only)	PROMs Ribbons
153	King Faisal Specialist Hospital and Research Center (KFSHRC) - Riyadh	Saudi Arabia	Riyadh		
206	Dr. Soliman Fakeeh Hospital	Saudi Arabia	Jeddah		
220	Johns Hopkins Aramco Healthcare	Saudi Arabia	Dhahran		

DSFH Jeddah was recognized in [Newsweek's World's Top 250 Hospitals 2026](#), highlighting the Group's ability to deliver care standards that are benchmarked against top international providers.

This recognition places the hospital among a select group of leading healthcare institutions globally, and one of three hospitals across the KSA, reflecting **strength across the areas that matter most in hospital quality**, including clinical excellence, patient outcomes, reputation among medical professionals, and patient experience.

Saudi Arabia Q Search...

Rank	Hospital Name	Score	City	Footnote	PROMs Ribbons
1	King Faisal Specialist Hospital and Research Center (KFSHRC) - Riyadh	92.70%	Riyadh		
2	Dr. Soliman Fakeeh Hospital	92.28%	Jeddah	2	
3	Johns Hopkins Aramco Healthcare	88.63%	Dhahran	2	
4	MOH-King Abdullah Medical City - Makkah	88.52%	Makkah		
5	MOH-King Saud Medical City - Riyadh	88.49%	Riyadh		

This recognition reinforces Fakeeh Care Group's position as the leading private healthcare services provider in Saudi Arabia.

A key driver to this recognition was **our performance in patient-reported outcome measures, or PROMs**, which assess how patients themselves report improvements in their symptoms, function, and quality of life following treatment. **Within Newsweek's World's Top 250 Hospitals 2026, Dr. Soliman Fakeeh Hospital Jeddah is one of only nine hospitals globally to receive five ribbons for PROMs, and the only hospital in Saudi Arabia to achieve that distinction.**

# Building on its market leading quality of care, DSFH Jeddah earns the Gold Planetree for patient-centered care

DSFH Jeddah achieved the Person-Centered Care Certification at the Gold level from Planetree International



Dr. Soliman Fakeeh Hospital Jeddah was awarded Planetree Gold Certification for Person-Centered Care, an internationally recognized distinction granted to healthcare organizations that **demonstrate a deep and sustained commitment to placing patients, families, and caregivers at the center of care delivery.**

The certification reflects the hospital's strength in creating an environment where **care is delivered with dignity, empathy, transparency, and partnership**, while ensuring that **patients are informed, heard, and actively involved in decisions relating to their treatment and recovery.**

It also recognizes **the importance of staff engagement and organizational culture in shaping the overall patient experience.** This milestone is important because it **demonstrates that the hospital's quality agenda extends beyond clinical performance alone and is equally focused on how care is experienced across every touchpoint of the patient journey.**



# 1Q-2026 RESULTS



# Revenue of SAR 724 million, up 3.3% YoY; New Business Revenue up 78% YoY driven by DSFH Riyadh and Madinah

## Revenue

**SAR 724 M**

▲ 3% y-o-y

## Gross Profit

**SAR 140 M**

▼ 21% y-o-y / 19% margin

## New Business Revenue (DSFH Riyadh & Madinah)

**SAR 106 M**

▲ 78% y-o-y

## Total Patients Served<sup>1</sup>

**438,697**

▲ 1% y-o-y / 73% Occupancy

## EBITDA<sup>2</sup>

**SAR 97 M**

▼ 20% y-o-y / 13% margin

## New Business Outpatients (DSFH Riyadh & Madinah)

**70,999**

▲ 62% y-o-y

## Net Profit

**SAR 26 M**

▼ 61% y-o-y / 4% margin

## Attributable Net Profit

**SAR 38 M**

▼ 47% y-o-y; EPS 0.17

## New Business Inpatients (DSFH Riyadh & Madinah)

**3,281**

▲ 104% y-o-y

## 1Q-2026 Highlights

- Group revenue reached **SAR 724 million in 1Q26**, up **3.3% YoY**, despite this year's sizeable Ramadan and Eid seasonality impact; New Business growth was a key driver as DSFH Riyadh and DSFH Madinah maintained their steep trajectories.
- New Business revenue, which includes DSFH Riyadh and DSFH Madinah, rose to **SAR 106 million, up 78% YoY**, driven by continued ramp-up at DSFH Riyadh and a full quarter of operations this year versus no contribution in 1Q25; Mature Business revenue was **SAR 618 million, 3.6% lower YoY**, mainly reflecting seasonality.
- The Group served **438,697 patients in 1Q26, up 1% YoY**, with inpatient admissions up **11%** and surgical procedures up **17%**, supporting continued case-mix improvement and healthy patient conversion rates; on a rolling 12-month basis, patients served, inpatient admissions, and surgeries grew **8%, 12%, and 16%, respectively**.
- New Business, served **74,280 patients in 1Q26, up 64% YoY**, serving **62%** more outpatients, **104%** more inpatients, and performing **118%** more surgical procedures YoY.
- Despite the Group's effort on cost control, the investment on ramping up new business and the seasonal headwind have caused significant impact on profitability compared to the same period of last year; while the Group ended the quarter with **SAR 723 million** in liquid funds and a net cash position of **SAR 59 million**.


<sup>1</sup> The Group calculates Patients Served as the total of outpatients, inpatients, and home healthcare cases served during the period.

<sup>2</sup> The Group calculates EBITDA as Earnings Before Interest and Tax (EBIT) plus depreciation and amortization, and non-cash Long-term Incentive Plan (LTIP).


# Patients served continues to grow YoY, with throughput progressively shifting towards higher-acuity care

- The Group served **438,697 patients in 1Q26, up 1% YoY** on a reported basis. On a rolling-twelve-month basis, which provides a cleaner read of the underlying trajectory, patients served grew **8%**, inpatient admissions grew **12%**, and surgical activity grew **16%**, with the case-mix shift outpacing overall volume growth.
- The Group operated **546 beds** at quarter-end, up from **460** a year earlier, with consolidated inpatient utilization reflecting the larger bed base in 1Q26 compared to 1Q25.
- Throughput continued to shift toward higher-acuity care, with inpatient admissions up **11% YoY to 12,478** and surgical procedures up **17% to 6,446**. The shift reflects the continued integration of higher-complexity service lines at DSFH Riyadh and DSFH Madinah alongside sustained sub-specialty depth in Jeddah.
- New Business continued to scale strongly, serving **74,280 patients, up 64% YoY**, driven by Riyadh's continued ramp-up and Madinah's this quarter of operations versus no contribution in 1Q25; serving **62% more outpatients, 104% more inpatients, and 118% more surgical procedures YoY**. The segment now contributes a structurally larger share of consolidated activity than at any point since the IPO.
- Year to date through 30 April 2026, the Group served **3% more outpatients, 14% more inpatients, and 21% more surgical procedures than in the comparable period of 2025**.


## Operational Beds (Beds / occupancy %)




## Outpatient Visits (000' of visits excluding follow-ups)



## Inpatient Admissions (000' of admissions)




## Surgeries (Number of surgical procedures)




# Revenue growth was driven by operational capacity expansion, New Business ramp-up, and higher-acuity mix

## Revenue Contribution by Segment & Geography



## Revenue Bridge (SAR mn)



- 1Q26 revenue grew **3.3% YoY to SAR 724 million**, driven by New Business revenue growth of **78% YoY to SAR 106 million**, led by Riyadh's continued ramp-up and Madinah's contribution in 1Q26. On a rolling-twelve-month basis, Group revenue reached **SAR 3.1 billion (+11% YoY)**, with Mature Business revenue up **6%** and New Business revenue up **63%**.
- Mature Business revenue read **SAR 618 million, 3.6% lower YoY**. The movement reflects this year's lengthier seasonal impact on our business, lower value of claims at Medical Fakeeh, and an optimization in the Group's O&M agreement.
- Healthcare contributed **90%** of consolidated revenue, growing **2% YoY to SAR 649 million**. The remaining **10%** was contributed by Education (**SAR 31 million, +8% YoY**) on continued enrollment growth at Fakeeh College for Medical Sciences, Technology (**SAR 16 million, +5x YoY**) as the business continues to build a recurring revenue base, and Medical-Related (**SAR 28 million, -12% YoY**).

# New business increased its operational capacity, yet EBITDA was held flat YoY

## Patients served

74,280

▲64% YoY / ▲91% vs. 1Q24

## New Business Revenue

SAR 106 M

▲78% YoY / ▲132% vs. 1Q24

## Revenue scale-up

2.3 x


1Q24 → 1Q26

## Revenue CAGR

+52%

Two-year compound annual


## New Business Revenue & EBITDA progression | 1Q24 – 1Q26




- Volumes scaled with continued case-mix shift toward higher-acuity care.** New Business served 74,280 patients in 1Q26, up 64% YoY, with inpatient admissions up 104% and surgical procedures up 118%. Starting from the 1Q24 baseline, surgical volumes have grown 223% and inpatient admissions 139%, against 89% growth in OPD visits.
- EBITDA loss held flat YoY despite Madinah's full-quarter negative contribution.** New Business EBITDA loss read SAR (28.1) million in 1Q26, broadly in line with SAR (28.6) million in 1Q25 and narrowing sequentially from SAR (34.4) million in 2Q25, when DSFH Madinah commenced operations.
- New Business EBITDA is approaching an inflection point.** Although the combined New Business operational beds increased to 173 in 1Q26, from 70 in 1Q24, this additional cost did not widen the New Business EBITDA loss on YoY basis. With segment EBITDA loss narrowing sequentially since 2Q25 and Madinah's run-rate continuing to build, the segment is progressing toward its consolidated breakeven trajectory.

# Cost discipline weathers seasonality impact & New Business ramp up costs weigh on profitability


Cost of Sales (% of Revenue)




Gross Profit (SAR mn / Margin)




Mature Business Gross Profit\*




SG&A (SAR mn / % of Revenue)



EBITDA (SAR mn / Margin)



Mature Business EBITDA\*




- Cost of Sales rose to **SAR 584 mn in 1Q26**, taking gross profit to **SAR 140 mn at a 19% margin** on the absence of the seasonally deprived revenue. Despite the controlled spending YoY and lower from 4Q25 by **SAR 45 mn**, **EBITDA reached SAR 97 mn at a 13% margin in 1Q26** in light of suppressed revenue. Factors other than seasonality are:
  - Materials & consumables remained stable at **23% of revenue, against 24% in 1Q25**, reflecting procurement discipline and integrated sourcing across the network.
  - **Salaries and related benefits rose to 43% of revenue in 1Q26 from 39% in 1Q25** driven by DSFH Madinah's front-loaded clinical staffing ahead of full occupancy added a layer of fixed personnel costs that had no equivalent in 1Q25.
  - SGAs in the quarter were only **1% up year on year** and as a percentage of revenue improved to **12.7% in 1Q26 from 13.0% in 1Q25**, masked by the lower revenue base but reflecting early benefits from cost avoidance initiatives and the centralization of non-medical support functions.
  - Competitive pressure required continued investment in talent retention to protect service quality and sub-specialty depth.
  - Lower value of claims in Medical Fakeeh, coupled with an optimization in the Group's O&M contracts
- The New Business EBITDA loss for the quarter was **SAR 28.1 mn**, broadly in line with the **SAR 28.6 mn** loss recorded in 1Q25, when only DSFH Riyadh was ramping and DSFH Madinah had not yet opened. The fact that adding Madinah operations on top of Riyadh has not widened New Business drag is an indicator of how Riyadh's contribution is largely offsetting Madinah's start-up costs.


# Seasonal impact on revenue and investment on new business compresses attributable profits

- Group net profit was **SAR 26.2 million in 1Q26 (1Q25: SAR 67.4 million)**, with profit attributable to shareholders at **SAR 38.4 million (1Q25: SAR 72.2 million)**. The reported decline reflects the growth in new business, the lengthier seasonal impact on revenues; lower value of claims at Medical Fakeeh, and an optimization in the Group's O&M agreement.
- Finance costs rose to **SAR 17 million (1Q25: SAR 10 million)**, primarily reflecting working capital financing costs related to DSFH Madinah & DSFH Riyadh.
- Mature Business attributable profit was **SAR 71 million in 1Q26 (1Q25: SAR 100 million)**. On a rolling-twelve-month basis, the Group generated over **SAR 256 million** of attributable profits, providing a clearer view of the underlying earnings power of the platform than any single quarter in isolation.

Net Profit Bridge (SAR mn / Margin)\*




Attributable Net Profit (SAR mn)




\* Like-for-like figures are management estimates that adjust for the year-on-year shift in the Ramadan and Eid calendar; provided as supplementary management information.  
Investor Presentation • 1Q 2026

# Strong cash generation and benign debt levels retain liquidity headroom for the Group's expansion program


Group Liabilities & Equity (SAR mn)



Cash Balances<sup>2</sup> Progression (SAR mn)



Net Debt Progression<sup>2</sup> (SAR mn)



- Liquidity headroom remained strong. Cash and cash equivalents stood at **SAR 422m**, coupled with **SAR 301m** invested in government sukuk, taking total liquid funds to **SAR 723m** and preserving balance-sheet flexibility to support the Group's ongoing investment cycle.
- 1Q26 capex amounted to **SAR 48m**, as the Group continued to fund its network expansion, with DSFMC Alawali and DSFMC North Obhur completing construction and progressing through testing, commissioning, and Civil Defence submission ahead of their planned soft openings in the second half of 2026.
- Funding capacity remained sound. Total loans (short- and long-term) increased to **SAR 663m at 31 March 2026 (31 December 2025: SAR 632m)**, while the Group remained in a net cash position of **SAR 59m** on a cash-plus-sukuk basis, retaining sufficient liquidity headroom to support the Madinah ramp-up, upcoming medical center openings, and other growth initiatives without requiring additional external financing at this stage.

## Net Cash / EBITDA<sup>1&2</sup>

**(0.13)x**

Vs. (0.21) x as of 31 Dec 2025

## Debt / Equity

**0.18x**

Vs. 0.18x as of 31 Dec 2025

## Av. Receivables Days<sup>3</sup>

**103 days**

Vs. 108 as of 31 Dec 2025

## Cash Conversion Cycle

**92 days**

Vs. 81 as of 31 Dec 2025

<sup>1</sup>Excluding leases. <sup>2</sup>Cash balance as of March 2026 include Fakeeh's SAR 301 million investment in KSA government sukuk <sup>3</sup>Receivables days on March 2026 and December 2025 exclude Accounts Receivable from the Group's O&M contracts



# Expansion Program UPDATES



# The Group will introduce an operating hospital & 3 greenfield medical centers to its network in 2026

2026

## Dr. Mohamed Alfagih Hospital (pending)

Hospital



Riyadh

350 Beds

Ownership:  
100%

## DSFMC Alawali

Medical Center



Makkah

20 Clinics

Ownership:  
100%

## DSFMC North Obhur

Medical Center



Jeddah

22 Clinics

Ownership:  
100%

## DSFMC Al Zahra

Medical Center



Jeddah

60+ Clinics

Long-term  
lease

2029

## DSFH Masar

Hospital



Makkah

200 Beds

Long-term  
lease

2030

## DSFH South Obhur (Jeddah)

Hospital



Jeddah

300 Beds

Ownership:  
75%

2032

## DSFH Jizan

Hospital



Jazan

200 Beds

Long-term  
lease




**+1000 Beds**  
to be introduced to  
the Group by 2032



**+500 Clinics**  
to be introduced to  
the Group by 2032

# Overall, on track to deliver exponential growth





# Q&A



# APPENDICES



# Board members and leadership updates

## Dr. Zeyad Alhekail replaces Dr. Noor Abid on the Group's Board of Directors



Mr. Ammar Fakeeh  
Chairman



Dr. Manal Fakeeh  
Vice Chairman



Dr. Mazen Fakeeh  
Group President &  
Executive Member



Prof. Ayman A.  
Executive  
Board Member



Eng. Anees M.  
Independent  
Member



Dr. Zeyad Alhekail  
Independent  
Member



Prof. Deborah Gill  
Independent  
Member



Torben Hilbertz  
Independent  
Member

## Mr. Taha assumes the Group's CFO role, while Mr. Panos now leads the Group's investments & treasury



Prof. Ayman A.  
Group Senior VP



Dr. Samar B.  
VP, Group Quality  
Standards



Mr. Panagiotis C.  
VP, Group  
Investments &  
Treasury



Mr. Tamer A.  
VP, Group  
Operations



Dr. Ahmed Tabakh  
VP, Revenue Cycle  
Management



Mr. Taha Bin S.  
Group CFO



Dr. Tamara Sunbul  
Group Chief Info.  
Officer



Dr. Sohail B.  
CEO, Makkah  
Region Cluster



Dr. Thamer Nouh  
CEO, DSFH Riyadh



Dr. Nezar Khalifah  
CEO, DSFH  
Madinah



Dr. Mohammed Q.  
CEO, Medical  
Fakeeh



Prof. Mohammed A.  
Dean, Fakeeh  
College for Medical  
Sciences

## The Group's Board of Directors has established an Investment Committee



Investment Committee



Audit & Risk Committee



Nomination & Remuneration Committee

# Fakeeh Care Consolidated Income Statement

فقيه.

مجموعة فقيه للرعاية الصحية  
Fakeeh Care Group

SAR millions	1Q-2026	1Q-2025	YoY %
Revenue	724.1	701.0	3.3%
Costs of revenue	(584.3)	(524.9)	11.3%
<b>Gross profit</b>	<b>139.9</b>	<b>176.1</b>	<b>-20.6%</b>
<b>Gross profit margin</b>	<b>19.3%</b>	<b>25.1%</b>	<b>-5.8pp</b>
Other income	3.6	1.6	122.0%
General and administrative expenses	(72.8)	(74.5)	-2.3%
Selling and marketing expenses	(19.5)	(16.8)	15.5%
Long-term Incentive Plan	(1.2)	(2.3)	-49.3%
Impairment loss on receivables	(5.5)	(7.2)	-22.9%
<b>Operating profit</b>	<b>44.6</b>	<b>77.0</b>	<b>-42.1%</b>
<b>Operating Profit margin</b>	<b>6.2%</b>	<b>11.0%</b>	<b>-4.8pp</b>
Finance cost	(17.2)	(9.9)	73.1%
Finance income	6.6	7.7	-14.8%
<b>Profit before Zakat</b>	<b>34.0</b>	<b>74.8</b>	<b>-54.5%</b>
Zakat	(7.8)	(7.4)	5.6%
<b>Profit after Zakat</b>	<b>26.2</b>	<b>67.4</b>	<b>-61.2%</b>
<b>Profit margin</b>	<b>3.6%</b>	<b>9.6%</b>	<b>-6.0pp</b>
<b>Profit for the year attributable to:</b>			
Shareholders' of the Company	38.4	72.2	-46.8%
Non-controlling interest	(12.2)	(4.8)	152.5%
<b>Additional information:</b>			
EPS	0.17	0.31	-46.8%
EBITDA	96.6	121.1	-20.3%
<b>EBITDA margin</b>	<b>13.3%</b>	<b>17.3%</b>	<b>-3.9pp</b>

Earnings per share (EPS) is calculated based on attributable net profit and the weighted average number of shares which reads 230,000,000 shares for 1Q26 and 1Q25

# Fakeeh Care Consolidated Balance Sheet

فقيه.

مجموعة فقيه للرعاية الصحية  
Fakeeh Care Group

SAR 000'	31-Mar-26	31-Dec-25
<b>ASSETS</b>		
Property and equipment	2,511,781	2,498,755
Right-of-use assets	570,022	492,247
Intangible assets and goodwill	548,536	547,568
Investment properties	366	376
Financial asset at amortized cost	300,617	298,126
Prepayments and other non-current assets	24,167	22,244
Other long-term receivables	140,315	144,748
<b>Non-current assets</b>	<b>4,095,804</b>	<b>4,004,064</b>
Inventories	206,107	196,293
Accounts and other receivables	974,663	974,978
Contract assets	68,468	39,798
Prepayments and other current assets	171,411	174,382
Cash and cash equivalents	421,911	439,162
<b>Current assets</b>	<b>1,842,560</b>	<b>1,824,613</b>
<b>TOTAL ASSETS</b>	<b>5,938,364</b>	<b>5,828,677</b>

## EQUITY

Share capital	232,000	232,000
Treasury shares	(2,000)	(2,000)
Share premium	1,653,473	1,653,473
Retained earnings	1,328,143	1,288,560
<b>Equity attributable to shareholders of the Company</b>	<b>3,211,616</b>	<b>3,172,033</b>
Non-controlling interests	414,606	409,353
<b>Total equity</b>	<b>3,626,222</b>	<b>3,581,386</b>

SAR 000'	31-Mar-26	31-Dec-25
<b>LIABILITIES</b>		
Long-term loans	334,000	334,000
Lease liabilities	542,364	481,162
Employees' end of service benefits	321,819	312,996
<b>Non-current liabilities</b>	<b>1,198,183</b>	<b>1,128,158</b>
Short-term loans	329,427	297,543
Current portion of lease liabilities	72,210	63,662
Accounts payables	356,193	362,234
Accrued and other current liabilities	317,998	365,403
Accrued zakat	38,131	30,291
<b>Current liabilities</b>	<b>1,113,959</b>	<b>1,119,133</b>
<b>Total liabilities</b>	<b>2,312,142</b>	<b>2,247,291</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5,938,364</b>	<b>5,828,677</b>

## Additional information:

(Net Cash) Net Debt	(59,100)	(105,745)
Total debt (including leases)	555,474	439,079
Net Debt / Equity	(0.016)	(0.030)
Total Net Debt (incl. leases) / Equity	0.153	0.123
12 months rolling EBITDA	471,789	496,326
Net Debt / EBITDA	(0.125)	(0.213)
Total Debt / EBITDA	1.18	0.88

# Forward-looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as “according to estimates”, “anticipates”, “assumes”, “believes”, “could”, “estimates”, “expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company’s business and management, its future growth or profitability and general economic and regulatory conditions and other matters affecting it.

These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and its investments, including, among other things, the development of its business, financial condition, prospects, growth, strategies, as well as the trends in the industry and macroeconomic developments in the Kingdom of Saudi Arabia. Many of these risks and uncertainties relate to factors that are beyond the Company's control or accurate estimation, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and any changes in applicable laws or regulations or government policies. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not otherwise occur and past performance shall not be taken as a guarantee of future results. No representation or warranty is made pertaining to any forward-looking statement made by the Company. The Company does not intend to update, supplement, amend or revise any such forward-looking statement whether as a result of new information, future events or otherwise. Nothing in the Information shall be construed as a profit forecast.

The Information may include financial information that are not defined or recognized under the International Financial Reporting Standards (IFRS). These measures are derived from the Company’s consolidated financial statements and provided as additional information to complement IFRS measures. Any financial information provided by the Company should not be considered in isolation or as a substitute for analysis of the Company’s financial information as reported under the IFRS.

# About Fakeeh Care Group

Established in 1978 by the late Dr. Soliman Fakeeh, the Fakeeh Care Group stands as a pioneer in integrated healthcare services in Saudi Arabia. Our comprehensive healthcare offering includes our core healthcare services ranging from ambulatory care to secondary and tertiary care, supported by Emergency Medical Services and Fakeeh Home Healthcare. Additionally, our offerings are enhanced by our industry-leading academic healthcare programs. Building on a strong track record of growth in our home city of Jeddah, the Group embarked on a Kingdom-wide expansion strategy to bring our well proven hub-and-spoke model and medical support services to major cities across Saudi Arabia.

**In June 2024, Fakeeh Care Group successfully concluded its initial public offering (IPO) on the Tadawul.** The IPO raised gross proceeds of SAR 2.9 billion (US\$ 764 million) for the Company and the Selling Shareholders of which SAR 1.7 billion will be used to support and accelerate the Group's growth strategy.

## For further information, please contact:

Fakeeh Care Group

Investors Relations

e-mail: [investors@fakeeh.care](mailto:investors@fakeeh.care)

# THANK YOU